Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 1/20 | 0.37 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.37 |
| ▸ | SNCA | P37840 | 2/20 | 0.36 |
| ▸ | TSHR | P16473 | 4/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.35 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.35 |
| ▸ | RECQL | P46063 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.35 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.33 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1665635 | 0.89 | CYP1A2 (0.36) | CYP1A2PDK1SNCATSHRALDH1A1 | |
| SCHEMBL1665240 | 0.84 | PDK1 (0.40) | CYP1A2PDK1SNCATSHRALDH1A1 | |
| SCHEMBL12348810 | 0.81 | CYP1A2 (0.57) | CYP1A2TSHRALDH1A1CYP3A4GPR35 | |
| SCHEMBL10213406 | 0.81 | TSHR (0.56) | CYP1A2TSHRALDH1A1CYP3A4GPR35 | |
| SCHEMBL27485132 | 0.79 | PARP1 (0.37) | CYP1A2PDK1SNCAALDH1A1CYP3A4 | |
| SCHEMBL888140 | 0.77 | CYP1A2 (0.40) | CYP1A2PDK1SNCATSHRALDH1A1 | |
| SCHEMBL888064 | 0.77 | CYP1A2 (0.44) | CYP1A2PDK1SNCATSHRALDH1A1 | |
| SCHEMBL14676339 | 0.77 | CYP1A2 (0.40) | CYP1A2PDK1SNCATSHRALDH1A1 | |
| SCHEMBL2064927 | 0.77 | FBP1 (0.46) | CYP1A2PDK1SNCATSHRCYP3A4 | |
| SCHEMBL16576676 | 0.76 | SNCA (0.40) | CYP1A2PDK1SNCATSHRALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2307565-B1 | REVERSIBLE NUCLEOSIDES AND NUCLEOTIDES TERMINATORS AND THEIR USE IN DNA SEQUENCING | LASERGEN INC (US) | 2017-11-29 | — | — | EP | disclosed |
| US-9200319-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2015-12-01 | — | — | US | disclosed |
| CN-102264917-B | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN INC | 2015-06-10 | — | — | CN | disclosed |
| US-20150140559-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2015-05-21 | — | — | US | disclosed |
| US-8877905-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2014-11-04 | — | — | US | disclosed |
| US-20140051848-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2014-02-20 | — | — | US | disclosed |
| CN-103588839-A | Nucleotides and nucleosides and method for their use in DNA sequencing | LASERGEN INC | 2014-02-19 | — | — | CN | disclosed |
| US-8497360-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2013-07-30 | — | — | US | disclosed |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | AGILENT TECHNOLOGIES, INC. | 2013-02-07 | — | — | US | disclosed |
| US-8148503-B2 | Nucleotides and nucleosides and methods for their use in DNA sequencing | LASERGEN, INC. (US) | 2012-04-03 | — | — | US | disclosed |
| CN-102264917-A | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | — | 2011-11-30 | — | — | CN | disclosed |
| EP-2307565-A2 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | Lasergen, Inc. (US) | 2011-04-13 | — | — | EP | disclosed |
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | AGILENT TECHNOLOGIES, INC. | 2010-02-18 | — | — | US | disclosed |
| WO-2009152353-A2 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | LASERGEN, INC. (US) | 2009-12-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100041041-A1 | NUCLEOTIDES AND NUCLEOSIDES AND METHODS FOR THEIR USE IN DNA SEQUENCING | UNG, NT5C2, NT5E | CYP1A2 1691/4885PDK1 4582/4885SNCA 2925/4885 |
| US-20130035237-A1 | Nucleotides and Nucleosides and Methods for their Use in DNA Sequencing | UNG, NT5C2, NT5E | CYP1A2 1691/4885PDK1 4582/4885SNCA 2925/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.